At CRISPR Therapeutics, we are focused on developing transformative gene-based medicines for serious human diseases
We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases
Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.
Your request has been submitted successfully.
Knowledge
Davos 2025 Highlights | World Economic F
[embed]https://youtu.be/G7Mh0MBEJBA[/embed].
Collaboration for the Intelligent Age. 2
OverviewGeo-economic fragmentation, g.
What does it take to put Spot to work? |
[embed]https://www.youtube.com/watch?v=_Ux-N-.
THE HUMAN FUTURE: A Case for Optimism
[embed]https://youtu.be/o48X3_XQ9to[/embed].
